

The Seventieth World Health Assembly, having considered the report of the 2016 Pandemic Influenza Preparedness (PIP) Framework Review Group and the reports of the Secretariat contained in documents A70.17 and A70.57, decided:

1. To recall the World Health Organization's mandate as the directing and co-ordinating authority on international health work, and its role under the International Health Regulations (2005) in global outbreak alert and response to public health crises;
2. To reaffirm the importance of the PIP Framework in addressing present or imminent to human health from influenza viruses with pandemic potential, and emphasize its critical function as a specialized international instrument that facilitates expeditious access to influenza viruses of human pandemic potential, risk analysis and the expeditious fair and equitable sharing of vaccines and other benefits;
3. To emphasize the importance of prioritizing and supporting global pandemic influenza preparedness and response, including through the strengthening of domestic seasonal influenza virus surveillance and manufacturing capacities and international coordination and collaboration through the Global Influenza Surveillance and Response System (GISRS) to identify and share influenza viruses with pandemic potential rapidly;
4. To acknowledge the critical role of the WHO Global Influenza Surveillance and Response System (GISRS) in the identification, risk analysis and sharing of influenza viruses with human pandemic potential to allow rapid development of diagnostics, vaccines and medicines;
5. To commend the successful conclusion of the work of the 2016 PIP Framework Review Group
6. To request the Director-General:
 - a. to take forward expeditiously the recommendations of the PIP Framework Review Group's report;
 - b. regarding the Review Group's recommendations concerning seasonal influenza and genetic sequence data, to conduct a thorough and deliberative analysis of the issues raised, including the implications of pursuing or not pursuing possible approaches, relying on the 2016 PIP Framework Review and the expertise of the PIP Advisory Group, and transparent consultation of Member States and relevant stakeholders, including the GISRS;
 - c. to continue encouraging manufacturers of influenza vaccines, antivirals and other products relevant to pandemic influenza preparedness and response to engage in PIP Framework efforts, including by making annual Partnership Contributions and entering into Standard Material Transfer Agreement 2s;
 - d. to request the External Auditor to perform an audit of PIP Partnership Contribution funds to: 1) provide assurances that the WHO financial regulations have been appropriately applied in the use of funds and that the financial information reported is accurate and reliable and; and 2) provide recommendations to further increase the transparency of reporting on the linkages between expenditure and technical impact.
 - e. to continue consultations with the Secretariat of the CBD and other relevant international organizations, as appropriate;
 - f. to report to the Seventy-first World Health Assembly, through the Executive Board, on progress in implementing this decision, including the status of the recommendations contained in the report of the PIP Framework Review Group ; and make recommendations on further action.